With a one year PEG ratio of 0.17, Arcturus Therapeutics Holdings Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.16% of US stocks.
ARCT's price/sales ratio is 86.88; that's higher than the P/S ratio of 97.01% of US stocks.
As for revenue growth, note that ARCT's revenue has grown -45.87% over the past 12 months; that beats the revenue growth of only 4.56% of US companies in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Arcturus Therapeutics Holdings Inc are LOGC, EVGN, ORMP, CRIS, and PULM.
First and foremost, the market didn't hear what it wanted from Federal Reserve Chair Jerome Powell. One way to "punt" on that difficult question is to buy Catalent -- recently added to the S&P 500 to the chagrin of Tesla bulls -- which has manufacturing agreements with Arcturus, Moderna and AstraZeneca, among others.
SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually: * TIDES: Oligonucleotide and Peptide Therapeutics scientific conference Presentation Date: Wednesday, September 9, 2020 Time: On-line * Baird Global Healthcare Conference Presentation Date: Wednesday, September 9, 2020 Time: 1:25 p.m. ET * Citi 15th Annual BioPharma Conference Panel Date: Thursday, September 10, 2020 Time: 1:30 p.m. ET * UBS ...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.